Cost minimization and budget impact analysis of rituximab versus infliximab, adalimumab, etanercept and abatacept in rheumatoid arthritis from a payer perspective in Brazil

被引：0
|
作者：
Saggia, M. G. [1 ]
Santos, E. A. [1 ]
Nasciben, V [1 ]
机构：
[1] Roche Brazil, Sao Paulo, Brazil
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)70821-4
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A260 / A260
页数：1
相关论文
共 50 条
  • [41] Comparing Abatacept to Adalimumab, Etanercept and Infliximab as First or Second Line Agents in Patients with Rheumatoid Arthritis. Experience from the RHUMADATA® Clinical Database and Registry
    Coupal, Louis
    Haraoui, Boulos
    Bessette, Louis
    Raynauld, Jean-Pierre
    Pelletier, Jean-Pierre
    Massicotte, Frederic
    Remillard, Marie-Anais
    Sauvageau, Diane
    Villeneuve, Edith
    Choquette, Denis
    JOURNAL OF RHEUMATOLOGY, 2015, 42 (07) : 1314 - 1314
  • [42] Comparing Abatacept to Adalimumab, Etanercept and Infliximab As First Line Agents in Patients with Rheumatoid Arthritis. Experience from the Rhumadata® Clinical Database and Registry.
    Choquette, Denis
    Bessette, Louis
    Fortin, Isabelle
    Haraoui, Boulos
    Pelletier, Jean Pierre
    Raynauld, Jean-Pierre
    Remillard, Marie-Anais
    Sauvageau, Diane
    Villeneuve, Edith
    Coupal, Louis
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S676 - S677
  • [43] Budget impact analysis of including biosimilar adalimumab on formulary: A United States payer perspective
    Chaplin, Stephen
    van Stiphout, Joris
    Chen, Anna
    Li, Edward
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2024, 30 (11): : 1226 - 1238
  • [44] The cost-effectiveness of abatacept versus rituximab in patients with rheumatoid arthritis: A perspective of the Canadian publicly funded health care system
    Yuan, Y.
    Maier-Moldovan, M.
    Maclean, R.
    L'Italien, G. J.
    VALUE IN HEALTH, 2008, 11 (03) : A257 - A257
  • [45] COST PER RESPONSE OF CERTOLIZUMAB PEGOL VERSUS ADALIMUMAB AMONG BIOLOGIC -NAIVE PATIENTS WITH MODERATE OR SEVERE RHEUMATOID ARTHRITIS FROM THE US PAYER PERSPECTIVE
    Chua, A.
    Lee, E.
    Ralston, P.
    Senecal, M.
    Stark, J.
    Liu, R.
    Yassine, M.
    Low, R.
    Sun, Y.
    VALUE IN HEALTH, 2018, 21 : S194 - S194
  • [46] COST-EFFECTIVENESS ANALYSIS OF ETANERCEPT AND INFLIXIMAB IN THE TREATMENT OF RHEUMATOID ARTHRITIS (RA) IN SPAIN
    Guijarro, P.
    Crespo, C.
    Brosa, M.
    VALUE IN HEALTH, 2012, 15 (07) : A448 - A448
  • [47] Budget impact analysis of the use of rituximab in the treatment of rheumatoid arthritis in Italy
    Benucci, Maurizio
    Iannazzo, Sergio
    Sabadini, Luciano
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2009, 10 (01) : 19 - 31
  • [48] Rituximab in the treatment of rheumatoid arthritis patients in Italy: a budget impact analysis
    Benucci, M.
    Iannazzo, S.
    Zaniolo, O.
    Sabadini, L.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (05) : 722 - 727
  • [49] Real-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: results of the CREATE registry
    M. Cárdenas
    S. de la Fuente
    P. Font
    M. C. Castro-Villegas
    M. Romero-Gómez
    D. Ruiz-Vílchez
    J. Calvo-Gutiérez
    A. Escudero-Contreras
    M. A. Casado
    J. R. Del Prado
    E. Collantes-Estévez
    Rheumatology International, 2016, 36 : 231 - 241
  • [50] A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness
    Chen, Y-F
    Jobanputra, P.
    Barton, P.
    Jowett, S.
    Bryan, S.
    Clark, W.
    Fry-Smith, A.
    Burls, A.
    HEALTH TECHNOLOGY ASSESSMENT, 2006, 10 (42) : 1 - +
12345